The mm Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the mm Hub cannot guarantee the accuracy of translated content. The mm and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.
Now you can support HCPs in making informed decisions for their patients
Your contribution helps us continuously deliver expertly curated content to HCPs worldwide. You will also have the opportunity to make a content suggestion for consideration and receive updates on the impact contributions are making to our content.
Find out more
Create an account and access these new features:
Bookmark content to read later
Select your specific areas of interest
View mm content recommended for you
CARTITUDE-4 MRD negativity analysis: Cilta-cel for len-refractory MM
|
MRD is an increasingly recognized prognostic marker in MM, providing a sensitive measure for response to therapy. Sustained MRD negativity ≥12 months has been associated with longer PFS and OS. As treatment strategies evolve, MRD is under evaluation as a predictor of long-term outcomes in clinical trials for MM.1 During the ASH congress 2024, Rakesh Popat presented the latest data, including an MRD analysis, from the phase III CARTITUDE-4 trial (NCT04181827), which compared cilta-cel with SoC therapy for the treatment of lenalidomide-refractory MM (N = 419).1 |
| Key learnings |
| Among patients evaluable for MRD, 85.6% of those treated in the cilta-cel arm (n = 139) observed MRD negativity at a sensitivity of ×10⁻⁶, compared with 18.6% in the SoC group (n = 102) (OR 28.5; p < 0.0001). |
|
82.1% of patients treated in the cilta-cel arm observed sustained MRD negativity (≥12 months) at a sensitivity of ×10⁻⁵, compared with 25.2% in the SoC group (OR 12.3; p < 0.0001). |
| The 30-month PFS and OS were 93.2% and 97.3%, respectively, in patients treated with cilta-cel who achieved sustained MRD negativity ≥CR. |
| Patients treated with cilta-cel achieved deep (×10⁻⁶) and sustained MRD negativity ≥CR rates, which correlated with prolonged PFS and OS, supporting the prognostic value of MRD negativity in CAR T-cell therapy. |
Abbreviations: CAR, chimeric antigen receptor; cilta-cel, ciltacabtagene autoleucel; CR, complete response; MRD, measurable residual disease; OR, odds ratio; OS, overall survival; PFS, progression-free survival; SoC, standard-of-care.
References
Please indicate your level of agreement with the following statements:
The content was clear and easy to understand
The content addressed the learning objectives
The content was relevant to my practice
I will change my clinical practice as a result of this content
